Loading...
NPI 1447592308 · Wake Forest, NC · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Radeas LLC is a clinical medical laboratory provider located in Wake Forest, North Carolina. This profile covers 34 Medicare and 128 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Radeas LLC |
| Address | 907 Gateway Commons Cir Ste 100 |
| City | Wake Forest |
| State | NC |
| ZIP | 27587 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | March 19, 2013 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $34.3M |
| Medicare | $6.5M |
RADEAS LLC operates as a clinical medical laboratory with a clear operational focus on high-volume toxicology and drug-confirmation services; its Medicare and Medicaid top codes are dominated by definitive drug testing and presumptive screens (notably G0483, G0482 and 80307), and the code descriptors indicate the lab performs method-specific confirmatory testing with specimen validity procedures. COVID nucleic acid and antigen panels (U0004, U0005, 87635, 87811) appear in the mix but account for relatively small portions of revenue compared with toxicology services.
Revenue concentration is acute on the Medicare side: the provider’s top 3 Medicare codes (G0483, G0482, 80307) account for 90.1% of its total Medicare revenue, driven largely by G0483 which represents $4.5M and 69.2% of its Medicare receipts. This concentration means Medicare income is heavily dependent on a small set of high-complexity toxicology codes rather than a broad laboratory portfolio.
Medicaid revenue shows the same narrow service mix: the top 3 Medicaid codes (G0483, 80307, G0482) account for 90.6% of total Medicaid revenue, with G0483 alone contributing $23.5M (69.0% of Medicaid revenue) from 270.5K claims. The Medicaid revenue profile reinforces that the business model is centered on mass toxicology screening and confirmatory testing rather than routine clinical panels.
Payer mix is weighted toward Medicaid in scale: reported totals are $34.3M in Medicaid revenue versus $6.5M in Medicare revenue, so the provider is effectively Medicaid-dominated in overall dollars. That skew suggests contract and rate negotiations with state Medicaid plans will have oversized influence on the organization’s financial performance compared with Medicare.
Competitively, RADEAS is an unusually large supplier of definitive drug testing nationally and within North Carolina. On Medicare G0483 it ranks #5 of 1063 providers (100th percentile; labeled an extreme outlier) and on 80307 it ranks #22 of 4760 providers (100th percentile; extreme outlier), indicating national-level volume well above typical peers for those lab services. In Medicaid the provider’s G0483 volume ranks #2 of 113 in-state (99th percentile; extreme outlier) and 80307 ranks #5 of 362 (99th percentile), making RADEAS one of the dominant in-state performers for toxicology testing.
The data show meaningful payer-level payment differentials that affect unit economics: for G0483 the average paid per claim is $242 on Medicare versus $87 on Medicaid, and the provider processes 18.6K G0483 Medicare claims versus 270.5K G0483 Medicaid claims. These differences imply higher per-claim reimbursement from Medicare but much larger claim volume from Medicaid, shaping cash flow and margin drivers across the two payers.
RADEAS has been an established NPI since 2013-03-19 (~13 years ago), indicating more than a decade of operations to scale the high-volume toxicology business reflected in the claims and revenue data. That tenure combined with outsized ranks on key toxicology CPT/HCPCS suggests the organization has built significant capacity and market share for confirmatory drug testing.
High revenue concentration in a few codes and extreme outlier volumes create exposure to policy or reimbursement changes for those specific services; with the top 3 codes accounting for 90.1% of Medicare revenue and 90.6% of Medicaid revenue, any restrictions, coding edits, or rate adjustments targeting definitive drug testing or screening could materially affect overall revenue. Analysts should monitor state Medicaid contracting and national toxicology reimbursement updates given the provider’s concentrated dependence on these code families.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
34 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 18,550 | $240 | $4.5M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3,630 | $200 | $707.1K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 10,740 | $60 | $655.1K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,730 | $150 | $265.1K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 2,720 | $70 | $201.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 2,720 | $30 | $67.9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 460 | $110 | $52K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 520 | $50 | $26K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 150 | $40 | $6.1K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 210 | $20 | $3.4K |
Showing 1–10 of 34
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 34 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
34 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0483 | 2 | 80 | 70 | $240 | $291.1K |
| U0004 | 2 | 10 | 2,720 | $70 | $279.3K |
| U0005 | 6 | 20 | 310 | $20 | $158.1K |
| G0481 | 4 | 130 | 60 | $150 | $71.5K |
| G0482 | 2 | 120 | 80 | $190 | $40.3K |
| G0480 | 6 | 150 | 60 | $110 | $39.6K |
| 80307 | 3 | 380 | 100 | $60 | $35.4K |
| 84402 | 30 | 30 | 80 | $20 | $33.6K |
| 82670 | 24 | 40 | 50 | $30 | $25.2K |
| 86038 | 31 | 30 | 30 | $10 | $23K |
Showing 1–10 of 34
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
128 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 270,470 | $90 | $23.5M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 174,940 | $30 | $4.5M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 36,770 | $80 | $2.8M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 34,070 | $40 | $1.4M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 14,720 | $50 | $691.7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 11,440 | $50 | $606.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 12,430 | $20 | $186.4K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 3,620 | $30 | $94.2K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 680 | $60 | $38.9K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 2,390 | $20 | $38.3K |
Showing 1–10 of 128
How this provider's Medicaid billing volume and revenue compare to other North Carolina providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. North Carolina median
128 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 110 | 1,450 | $110 | $1.7M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 22 | 40 | 480 | $40 | $1.4M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 32 | 80 | 420 | $30 | $1.2M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 60 | 1,640 | $100 | $940.2K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 49 | 70 | 280 | $20 | $896.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 5 | 360 | 1,830 | $40 | $819.8K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 80 | 1,020 | $70 | $669.6K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 141 | 190 | 530 | $20 | $635.1K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 144 | 190 | 560 | $20 | $609.8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 12 | 150 | 860 | $50 | $586.6K |
Showing 1–10 of 128
Other providers in the same ZIP code as Radeas LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Wake Forest Pediatric Associates, PLLC | NC | Pediatrics Physician | $0 | $9.8M |
| Amazing Kids Of Nc, Inc. | NC | Community/Behavioral Health Agency | $0 | $7.5M |
| Trg Health Care Systems LLC | NC | Community/Behavioral Health Agency | $0 | $7.1M |
| Elias Ayli | NC | MOHS-Micrographic Surgery Physician | $1.1M | $0 |
| Edward Galiczynski | NC | Dermatology Physician | $1M | $0 |
| Patricia Matheis | NC | Specialist | $985.1K | $0 |
| Francisco Castillos | NC | Hematology & Oncology Physician | $534K | $0 |
| Duke University Health System Inc | NC | Diagnostic Radiology Physician | $150.8K | $14.1K |
| Daniel Henry | NC | Physical Therapist | $157.9K | $0 |
| Samantha Ward | NC | Optometrist | $112.6K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.